Bromelain and proteolytic enzymes: Postoperative edema vs bleeding concerns

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/bromelain-and-proteolytic-enzymes-postoperative-edema-vs-bleeding-concerns

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Introduction Bromelain, serrapeptase, and similar proteolytic (protein-digesting) enzymes are natural supplements sometimes promoted to reduce surgical swelling and pain. People often take them after operations (for example, dental extractions or soft-tissue surgery) in hopes of speeding healing. These enzymes indeed have anti-inflammatory effects and can ease pain. However, they also can thin the blood or interfere with clotting. That raises a particular concern after glaucoma filtration surgery (trabeculectomy), where a delicate “filtering bleb” must heal without bleeding. In this article, we review the evidence on their benefits and risks for postoperative recovery, with a special focus on bleeding (hyphema) and bleb complications after trabeculectomy. We will cover when (and if) it might be safer to start these supplements after surgery, which patients should avoid them, and how future studies could safely measure outcomes. How Bromelain and Serrapeptase Work Bromelain is a mixture of enzymes from pineapple stems (Ananas comosus). Serrapeptase (serratiopeptidase) is an enzyme from a bacterium found in silkworm intestines. Both are proteolytic enzymes that break down proteins. In the body, this gives them several effects: they can reduce inflammation and edema (swelling), dissolve certain blood clots, and potentially prevent excessive scarring. They are often taken orally as capsules (usually in an enteric coating so they survive the stomach).

Studies show these enzymes are absorbed in the gut and remain active in the bloodstream for hours () (). They help control inflammation by breaking down inflammatory mediators like bradykinin and serotonin (in the case of serrapeptase) () (). Both enzymes have been used in some settings to aid wound healing (for example, topical bromelain for burn debridement, and oral use in osteoarthritis and respiratory conditions).

... Continue reading at https://visualfieldtest.com/en/bromelain-and-proteolytic-enzymes-postoperative-edema-vs-bleeding-concerns

Transcript

SPEAKER_00 0:00

Introduction Bromolane, serapeptase, and similar proteolytic, protein-digesting enzymes are natural supplements sometimes promoted to reduce surgical swelling and pain. People often take them after operations, for example, dental extractions or soft tissue surgery, in hopes of speeding healing. These enzymes indeed have anti-inflammatory effects and can ease pain. However, they also can thin the blood or interfere with clotting. That raises a particular concern after glaucoma filtration surgery, trabeculectomy, where a delicate filtering bleb must heal without bleeding. In this article, we review the evidence on their benefits and risks for postoperative recovery, with a special focus on bleeding, hyphema, and bleb complications after trabeculectomy. We will cover when and if it might be safer to start these supplements after surgery, which patients should avoid them, and how future studies could safely measure outcomes. How bromalane and serapeptase work. Bromolane is a mixture of enzymes from pineapple stems, anonascomosis. Cerapeptase, ceraciopeptidase, is an enzyme from a bacterium found in silkworm intestines. Both are proteolytic enzymes that break down proteins. In the body, this gives them several effects. They can reduce inflammation and edema, swelling, dissolve certain blood clots, and potentially prevent excessive scarring. They are often taken orally as capsules, usually in an enteric coating, so they survive the stomach. Studies show these enzymes are absorbed in the gut and remain active in the bloodstream for hours. They help control inflammation by breaking down inflammatory mediators like bradykinin and serotonin, in the case of serapeptase. Both enzymes have been used in some settings to aid wound healing, for example, topical bromolane for burn debridment and oral use in osteoarthritis and respiratory conditions. Effects on swelling and pain. The primary claimed benefit is reduced postoperative swelling and pain. Some studies support mild benefits. Bromolane clinical trials. A systematic review of randomized trials after third molar extraction, wisdom tooth removal, found that bromolane improved patients' pain scores and overall quality of life in the week after surgery. However, that same review found no significant reduction in facial swelling or jaw trismus from bromolane. In other words, patients felt less pain but did not actually have noticeably less visible swelling after dental surgery. Bromolane, other surgeries. In a double-blind trial of women undergoing episiotomy, surgical cut at childbirth, six days of oral bromeline, given thrice daily, significantly reduced pain and speeds up wound healing compared to placebo. By day 7 and 14 postpartum, the bromolane group showed better healing scores on the Rita scale and reported less pain. In short, bromolane helped healing on a soft tissue surgical wound. This suggests bromalane does not impair healing. On the contrary, it appeared to help, possibly by reducing inflammation. Serapeptase, jaw surgery. Serapeptase has also shown some benefit for swelling after mouth surgery. In a head-to-head trial of 100 patients, 100 removed wisdom teeth, those given cera peptase after surgery had significantly less facial swelling on days 2 to 5 after surgery compared with dexamethasone, a steroid. Both arms saw improvement, but the steroid group had slightly faster effect. In other words, cera peptase moderately reduced postoperative edema, though steroids were even more effective. That study confirms serapeptase has real anti-edema action, just not as potent as strong steroids. In summary, some evidence, mostly from dentistry/slash-oral surgery, suggests bromolane and serapeptase can ease pain and somewhat reduce swelling. Their benefits seem modest compared to standard treatments, like steroids or NSAIDs, and not all studies agree. For example, in the meta-analysis of dental extraction, bromolane reliability on swelling was weak. But overall, patients do often report feeling better with these supplements. Still, the evidence base consists of relatively small studies or poor quality trials, so conclusions are tentative. Blood thinning effects and bleeding risk. Crucially, bromelane and serapeptase affect blood clotting. There is laboratory and clinical evidence they can thin the blood by inhibiting clot formation. Platelet inhibition, bromelane. In lab models, bromolane dramatically blocked platelets from clumping. One in vitro study showed bromolane completely prevented thrombin-induced platelet aggregation. Platelets did not clump together. Bromolane also reduced platelets sticking to endothelial cells. In rats given bromolane by mouth, 60 mg per kilogram, thrombus clot, formation in small vessels was significantly lower than control. In short, bromolane has strong antiplatelet and anti-thrombotic activity in animal studies. Fibrinolysis, cereptase. Cerrapeptase strongly digests fibrin, a key clot protein. A 2022 study measured cera peptase's fibrinolytic activity in vitro and found it can prevent blood coagulation at sufficient concentrations. It could practically dissolve an entire clot at 300 U milliliters. Cerapeptase achieved to 96.6% clot lysis in four hours. This shows powerful clot dissolving potential, similar to natokinase or plasmin. It broke down fibrin and kept blood from clotting in lab tubes. Effects on clotting tests. Clinical observations support these lab findings. Bromolane has been reported to prolong clotting time, for example, APTT in humans. One case report described a postpartum woman who drank pineapple juice, rich in bromolane, and developed secondary postpartum hemorrhage, excessive bleeding. The authors noted bromolane's anti-thrombotic and fibrinolytic properties, and that it caused a dose-dependent prolongation of APTT. The implication is that high bromaline intake can slow coagulation and worsen bleeding. Interaction with drugs. Some supplement interactions are known or theorized. For example, bromolane is listed as having a moderate interaction with clopidogrel, a prescription antiplatelet, meaning together they can increase bleeding risk. Likewise, health sources advise avoiding cereptase if taking aspirin, warfarin, or other blood thinners. Taken together, these findings mean patients on anticoagulants or antiplatelets should avoid added proteolytic enzyme supplements as bleeding risk is higher. Case reports of bleeding. Aside from general effects, rare case reports illustrate the danger of bleeding with these enzymes. A 2023 case report described secondary postpartum hemorrhage linked to pineapple juice consumption. The paper explicitly warned that bromomlane has proteolytic and antithrombotic effects, causing measurable delays in clotting. Another case report, 2021, involved a young woman with Beichetz disease who took cereptase chronically for thrombosis prophylaxis and leg swelling. She developed widespread echimoses, bruises on her body. The authors noted taking this proteolytic enzyme continuously to prevent thrombosis was likely responsible for her diffuse bleeding. These individual cases show that in predisposed patients, proteolytic enzymes can tip the balance toward bleeding. Of course, isolated reports cannot prove causation by themselves, but they do flag a real risk, especially when combined with other risk factors. Bleeding concerns after trabeculectomy. Trabeculectomy, glaucoma filter surgery, creates a small flap in the eye for fluid drainage, forming a raised area, bleb, under the conjunctiva. This bleb must heal properly to control eye pressure. Hyphema, blood in the front chamber, and bleb leaks are known glaucoma surgery complications. Published series and studies report that after trabeculectomy, hyphema is relatively common. One source notes about 8 to 11% of patients developed a hyphema after traculectomy in major glaucoma trials. In one surgical survey, about 24% of eyes had some postoperative hypema. Most hypemas after such surgery are small and clear blood on their own, often resolving without treatment. Bleb leaks and hypotony. Early bleb leaks can cause low eye pressure and fluid seepage. In one survey, surgical wound leaks, sometimes called bleb leaks, occurred in about 17% of trabeculectomies. Hypotony, very low pressure, then leads to other issues, risks of choroidal detachments or bleb failure. The key point is that even a small bleed or delayed clotting can have big effects after glaucoma surgery. If a hyphema persists or a bleb leak stays open, vision can suffer and the surgery can fail. For example, a clot blocking the new drainage path might raise eye pressure, or conversely, excessive fluid leak can cause hypotany. Studies warn that risk factors for major ocular hemorrhages, like suprachoroidal hemorrhage, include any systemic clotting issues or use of blood thinners. Azuara Blanco et al. list bleeding disorders or use of anticoagulants as risk factors for serious post-surgical eye bleeds. By analogy, if bromolane or serapeptase act like blood thinners, they could add to that risk. In short, the bleb is a very delicate healing site. It needs clots to form and scar tissue to seal the flap. Anything that inhibits clotting or accelerates fibrin breakdown could threaten bleb integrity, at least in theory. So far, there are no published reports specifically saying bleb leak occurred after bromolane, but given what we know, if bromolane serapeptase weakens clot formation, a microscopic bleeder might not stop quickly. This could increase the risk of visible hyphema, persistent bleeding, or bleb leak during the critical early healing period. As a result, many glaucoma surgeons advise caution. Timing after surgery. Some patients wonder if it's safer to delay these supplements until a couple of weeks after surgery. By two weeks post-trabeculectomy, the eye's initial wound healing phase is largely over. In general, surgery wounds, much of the early inflammation and edema subsides by one to two weeks. For example, most post-surgical swelling peaks in the first few days, and much of it is gone by two weeks in many wounds. Thus, starting bromolane serapeptase two weeks later would likely have little benefit for swelling, since the acute swelling is mostly resolved by then. However, does weighting improve safety? Once two weeks have passed, the bleb flap is more stable and scalpels no longer fully heal. Tensile strength increases with time. Delaying might reduce the risk of interfering with the initial clotting hemostasis. That said, bleb healing and remodeling continue for months. The fine scar needs the right growth and maintenance. It's unclear if starting bromolane later is truly harmless. Some risk technically remains, though likely smaller than giving it immediately. In practice, many surgeons would say, if you feel you need a supplement for pain swelling, discuss it with your eye doctor. They will consider if the potential relief is worth even a small risk of bleeding. Given the modest benefits and uncertain safety, most would caution against using these enzymes even after two weeks in a recent trabeculectomy patient, especially since the main period for swelling has passed. Which patients should avoid proteolytic enzymes? Certain patient groups should definitely avoid bromolane serapeptase around the time of eye surgery or any surgery. These include patients on blood thinners or antiplatelets, anyone taking aspirin, clopidogrel, plavox, warfarin, doax, heparin, or even high-dose fish oil garlic turmeric supplements should avoid adding bromolane or serapeptase. The combined effect could cause dangerous bleeding. Bleeding disorders or low platelets. Patients with hemophilia, von Willebrand disease, thrombocytopenia, or any tendency to bleed should not take these enzymes. History of ocular bleeding. If you've had episodes of eye hemorrhage, hyphema, or a known weak vessel like iris microhemangiomas, these supplements might worsen it. Also avoid if you had a prior suprachoroidal hemorrhage. Pregnant or breastfeeding women. Bromolane has been noted to possibly induce uterine bleeding or contractions in animal studies. It's usually advised against in pregnancy. Serapeptase safety in pregnancy is also unproven. Peptic ulcer or GI bleeding. Since these enzymes also thin blood, those with stomach ulcers, gastritis, or a recent GI bleed should avoid them. Children. There is no well-established dosing or safety data for growing children. Allergies. Anyone allergic to pineapple for bromelin or silkworm bacteria products for serapeptase should avoid them. Rarely, serapeptase could trigger unexpected immune reactions or eosinophilic pneumonia, per some reports. In short, if any reason to bleed or bruise is present, or if you are on anticoagulant drugs, do not take bromoline or serapeptase around your surgery. Even if you aren't on medications, having had glaucoma surgery places you in a high risk category for device failure if bleeding occurs. Use of these enzymes should be discussed with, and usually avoided by, your surgeon. Recommendations for clinical trials, safety endpoints. If a researcher were to design a trial testing bromolane serapeptase in postoperative patients, careful safety monitoring would be crucial. Here are suggested standardized safety endpoints to include bleeding events, systemic, log any bleeding episodes, nosebleeds, gum bleeding, heavy menstruation, bruising. Use established criteria for major minor bleeding, for example, ISTH definitions. Major bleed means intracranial, requiring transfusion or dropping hemoglobin to clinically relevant non-major as defined in drug trials. Laboratory markers. Monitor coagulation labs, PTAPTT, and platelet counts at baseline and during the trial. Optionally measure platelet function tests, e.g. PFA100 or aggregometry or thromboelastography, TEG Rotem. Track hemoglobin hematocrit to catch occult bleeding. Ocular bleeding. Specifically record any hyphema blood in the anterior chamber. Grade its severity, e.g. 1 plus, 2 plus, 3 plus, or a known scale. Note if it required any intervention like an anterior chamber washout or caused elevated eye pressure. Bleb integrity. Perform site testing, fluorescence to detect bleb leaks. Count any incident of wound leaks or thin ovascular blebs. Monitor intraocular pressure closely. A sudden drop, hypotony, e.g. IOP 5 mm hergrams, or spike might indicate a leak or bleed. Note any choroidal effusions on exam or ultrasound. Additional visual outcomes. Track best corrected visual acuity and visual field changes as indirect safety signals. A loss of vision due to bleeding, e.g., corneal blood staining, would be critical. General safety. Adverse events such as hospitalization for bleeding, GI bleed, intracranial hemorrhage, etc., of any cause should be recorded. Also monitor hepatic renal function if using high doses, since bromolane is metabolized and could stress organs in theory, rarely reported. In a trial report, it would be ideal to present both incidents, percentage of patients with event, and time to event. For ocular endpoints, standardized glaucoma surgery outcome definitions can be used, e.g., from the World Glaucoma Association, which define bleb outcomes. Overall, the trial should plan interim safety analyses focusing on bleed risk before considering efficacy. Conclusion: Bromolane, serapeptase, and related proteolytic enzyme supplements can modestly reduce pain and inflammation after surgery, but their blood thinning effects are real. In routine surgeries, their benefit risk may be acceptable, but in eye surgery, like trabeculectomy, the stakes are higher. Published studies and even case reports show these enzymes inhibit clotting and can worsen bleeding. Because postoperative eye bleeds, hyphema, and bleb leaks are already known risks, adding another bleeding factor could be dangerous. Doctors generally advise avoiding these supplements in the early postoperative period of a trabeculectomy, and certainly in patients on other blood thinners or with bleeding risk. Even if started after two weeks, any benefit for swelling is minimal, while any bleeding risk, though reduced, is still undesirable. For patients, always tell your surgeon about any supplements you take. If you're considering bromolane or cereptase to help with post-op swelling or eye comfort, discuss it first. Your doctor can help weigh whether you really need it and if there are safer alternatives. In research, careful monitoring of both clotting labs and eye exam findings would be needed to ensure safety before endorsing these products in this context. Sources. Clinical trials and reviews were used for these conclusions, including systematic reviews and RCTs on bromolane cereptase, laboratory studies on clotting, and case reports highlighting bleeding complications. Official glaucoma surgery complication guides warn that bleeding disorders and anticoagulant use raise eye bleed risks, reinforcing caution. All links to sources are available in the text version of this article. You can find the full article at VisualFieldTest.com. Thanks for listening. To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.